Retatrutide Weight Loss Hits 20.8% in Phase 3 Diabetes Trial

The next heavyweight in the weight-loss drug wars just posted its biggest numbers yet. New retatrutide weight loss data show Eli Lilly's investigational triple-hormone drug helped adults with type 2 diabetes and obesity shed an average of up to 20.8% of their body weight over 80 weeks. The full phase 3 results, published in The Lancet on September 29 and presented at the European Association for the Study of Diabetes (EASD) meeting in Milan, come from the TRIUMPH-2 trial of 1,152 adults across eight countries — and they position retatrutide as potentially the most powerful obesity drug ever tested in people with diabetes.

That last detail matters more than it sounds. Weight-loss drugs have historically worked less well in people with diabetes, so a therapy that tackles both conditions at once would fill a real gap: the vast majority of people with type 2 diabetes also live with obesity, and treating the two together has always been difficult. According to Lilly's announcement, participants started the trial with an average weight of 234.6 pounds, an average BMI of 38.2, and an average A1C of about 7.7% — a group for whom existing medicines often deliver only modest results.

Inside the retatrutide weight loss numbers

The retatrutide weight loss trial tested three weekly doses — 4 mg, 9 mg, and 12 mg — against placebo, with all participants also receiving diet and exercise counseling. Under the efficacy analysis Lilly highlights, average weight loss at 80 weeks was 12.7% at 4 mg, 19.1% at 9 mg, and 20.8% at 12 mg, compared with 4.0% on placebo. A second, more conservative analysis that counts everyone regardless of whether they stayed on treatment showed 11.9%, 16.8%, and 18.8% against 5.1% on placebo, MedicalDaily reported.

The headline figures get even bigger in the heaviest participants. Among people who started with a BMI of 35 or higher, the 12 mg dose produced an average loss of 23.4% — about 60.8 pounds. At the top dose, 47% of participants lost at least 20% of their starting weight and 31% lost at least 25%, versus 6% and 3% on placebo. And 59.5% of people on 12 mg no longer met the BMI criteria for obesity at all by the end of the trial.

Blood sugar improved in parallel. A1C fell by 1.4, 1.6, and 1.5 percentage points across the three doses versus 0.2 on placebo, and up to 40% of participants reached an A1C below 5.7% — the normal, non-diabetic range. The retatrutide weight loss came with cardiometabolic bonuses too: at the highest dose, triglycerides dropped 39.5%, non-HDL cholesterol fell 19.6%, systolic blood pressure declined 10.8 mmHg, and hsCRP, a marker of inflammation, plunged 58.3%, according to reporting on the Lancet paper.

Why retatrutide works differently

Retatrutide is a single molecule that activates receptors for three hormones: GIP, GLP-1, and glucagon. That makes it the first triple agonist in its class. For comparison, semaglutide — sold as Ozempic and Wegovy — targets GLP-1 alone, while tirzepatide — sold as Mounjaro and Zepbound — targets GLP-1 and GIP. Retatrutide adds glucagon, a hormone that acts mainly on the liver and the body's energy expenditure, which researchers believe helps explain the outsized results.

The extra pathway behind the retatrutide weight loss comes with trade-offs. Gastrointestinal side effects were the most common problem: diarrhea affected 27% to 34% of people on retatrutide versus 13% on placebo, nausea hit 14% to 28% versus 8%, and vomiting reached up to 15.7% versus 4.2%. An unusual skin sensation called dysesthesia showed up in 4.5% to 7.3% of retatrutide users compared with 0.7% on placebo. Treatment discontinuation due to side effects reached 11.6% at the 9 mg dose and 7.7% at 12 mg, versus 4.9% on placebo — and seven deaths occurred during the trial, which investigators judged unrelated to the study drug.

Independent experts struck a measured tone on the retatrutide weight loss figures. Philip Newland-Jones of the University of Southampton told The Pharmaceutical Journal that weight-loss drugs have tended to work less well in people with diabetes, "making the average of almost 21% weight loss with retatrutide especially impressive." But Helen O'Neil, a senior medicines optimization pharmacist with NHS North East and North Cumbria, cautioned that "head-to-head studies are needed to determine its place in treatment pathways" — a reminder that TRIUMPH-2 had no active comparator, so direct comparisons with Ozempic or Mounjaro remain guesswork.

What happens next

For now, despite the striking retatrutide weight loss numbers, the drug remains investigational and unavailable by prescription. Lilly says it plans to submit an application to the FDA in the first quarter of 2027, and a decision would typically take months after that. Price, insurance coverage, and how it stacks up directly against existing drugs are all unknown — and those unknowns are where the real-world story will be decided. The current generation of GLP-1 drugs already strains insurance budgets and sparks access fights; a more powerful successor will intensify both.

There is also a safety warning worth hearing now. MedicalDaily has reported that products sold as retatrutide are already appearing at medical spas and online sellers — and those products are not the drug tested in TRIUMPH-2, with contents, dose, and sterility that cannot be verified. Anyone curious about the results should bring them to a clinician and ask about approved options instead. "Results such as these may change what we set out to achieve with a single therapy for adults living with type 2 diabetes and obesity," said Dr. Juan P. Frías, medical director at the Los Angeles Institute for Metabolic Research, in Lilly's release — but that future is still on the other side of an FDA review.

Zoom out, and the retatrutide weight loss story is really about where medicine is headed: single drugs that treat obesity, diabetes, blood pressure, and cholesterol risk at once, rather than a handful of pills for each. If the retatrutide weight loss data hold up and the FDA application lands in early 2027 as planned, the next chapter — pricing, coverage, and who actually gets access — will matter more than the trial numbers. For continuing coverage of the drugs reshaping how we think about weight and metabolic health, follow GenZ NewZ's health section and the GenZ NewZ homepage.